Search

Your search keyword '"Lee, Pei-Chang"' showing total 317 results
Start Over Author "Lee, Pei-Chang"
317 results on '"Lee, Pei-Chang"'

4. Impact of body mass index in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, D’Alessio, Antonio, Fulgenzi, Claudia Angela Maria, Nishida, Naoshi, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Bengsch, Bertram, Vogel, Arndt, Balcar, Lorenz, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Cammarota, Antonella, Zanuso, Valentina, Pressiani, Tiziana, Pinter, Matthias, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., and Sharma, Rohini

Published
2023
Full Text
View/download PDF

5. Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Author

Celsa, Ciro, Cabibbo, Giuseppe, Fulgenzi, Claudia A.M., Scheiner, Bernhard, D’Alessio, Antonio, Manfredi, Giulia F., Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Saeed, Anwaar, Wietharn, Brooke, Pinter, Matthias, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, Phen, Samuel, Gampa, Anuhya, Pillai, Anjana, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Roehlen, Natascha, Thimme, Robert, Vogel, Arndt, Schönlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Galle, Peter R., Kudo, Masatoshi, Rimassa, Lorenza, Singal, Amit G., El Tomb, Paul, Ulahannan, Susanna, Parisi, Alessandro, Chon, Hong Jae, Hsu, Wei-Fan, Stefanini, Bernardo, Verzoni, Elena, Giusti, Raffaele, Veccia, Antonello, Catino, Annamaria, Aprile, Giuseppe, Guglielmini, Pamela Francesca, Di Napoli, Marilena, Ermacora, Paola, Antonuzzo, Lorenzo, Rossi, Ernesto, Verderame, Francesco, Zustovich, Fable, Ficorella, Corrado, Di Pietro, Francesca Romana, Battelli, Nicola, Negrini, Giorgia, Grossi, Francesco, Bordonaro, Roberto, Pipitone, Stefania, Banzi, Maria, Ricciardi, Serena, Laera, Letizia, Russo, Antonio, De Giorgi, Ugo, Cavanna, Luigi, Sorarù, Mariella, Montesarchio, Vincenzo, Bordi, Paola, Brunetti, Leonardo, Pinto, Carmine, Bersanelli, Melissa, Cammà, Calogero, Cortellini, Alessio, and Pinato, David J.

Published
2024
Full Text
View/download PDF

7. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, Scheiner, Bernhard, Fulgenzi, Claudia Angela Maria, D’Alessio, Antonio, Pomej, Katharina, Roig, Marta Bofill, Meyer, Elias Laurin, Che, Jaekyung, Nishida, Naoshi, Lee, Pei-Chang, Wu, Linda, Ang, Celina, Krall, Anja, Saeed, Anwaar, Stefanini, Bernardo, Cammarota, Antonella, Pressiani, Tiziana, Abugabal, Yehia I., Chamseddine, Shadi, Wietharn, Brooke, Parisi, Alessandro, Huang, Yi-Hsiang, Phen, Samuel, Vivaldi, Caterina, Salani, Francesca, Masi, Gianluca, Bettinger, Dominik, Vogel, Arndt, von Felden, Johann, Schulze, Kornelius, Silletta, Marianna, Trauner, Michael, Samson, Adel, Wege, Henning, Piscaglia, Fabio, Galle, Peter R., Stauber, Rudolf, Kudo, Masatoshi, Singal, Amit G., Itani, Aleena, Ulahannan, Susanna V., Parikh, Neehar D., Cortellini, Alessio, Kaseb, Ahmed, Rimassa, Lorenza, Chon, Hong Jae, Pinato, David J., and Pinter, Matthias

Published
2024
Full Text
View/download PDF

13. THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Author

Vithayathil, Mathew, primary, D'Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Celsa, Ciro, additional, Manfredi, Giulia, additional, Nishida, Naoshi, additional, Schoenlein, Martin, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Wege, Henning, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Hildebrand, Hannah, additional, Wu, Linda, additional, Ang, Celina, additional, Marron, Thomas U., additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Bettinger, Dominik, additional, Lin, Chun-yen, additional, Vogel, Arndt, additional, Scheiner, Bernhard, additional, Lee, Pei-Chang, additional, Huang, Yi-Hsiang, additional, Amara, Suneetha, additional, Muzaffar, Mahvish, additional, Naqash, Abdul Rafeh, additional, Zanuso, Valentina, additional, Pressiani, Tiziana, additional, Cabibbo, Giuseppe, additional, Dalbeni, Andrea, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Cortellini, Alessio, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, and Sharma, Rohini, additional

Published
2024
Full Text
View/download PDF

14. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy

Author

Scheiner, Bernhard, primary, Kang, Beodeul, additional, Balcar, Lorenz, additional, Radu, Pompilia, additional, Reiter, Florian P, additional, Adžić, Gordan, additional, Guo, Jiang, additional, Gao, Xu, additional, Yuan, Xiao, additional, Cheng, Long, additional, Gorgulho, Joao, additional, Schultheiß, Michael, additional, Khaled, Najib Ben, additional, Sinner, Friedrich, additional, D'Alessio, Antonio, additional, Pomej, Katharina, additional, Saborowski, Anna, additional, Schwacha-Eipper, Birgit, additional, Zarka, Valentina, additional, Lampichler, Katharina, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Himmelsbach, Vera, additional, Tesini, Giulia, additional, Wietharn, Brooke, additional, Huang, Yi-Hsiang, additional, Vivaldi, Caterina, additional, Masi, Gianluca, additional, Vogel, Arndt, additional, Schulze, Kornelius, additional, Trauner, Michael, additional, Stauber, Rudolf E., additional, Kudo, Masatoshi, additional, Dekervel, Jeroen, additional, Parikh, Neehar, additional, Dufour, Jean-François, additional, Prejac, Juraj, additional, Geier, Andreas, additional, Bengsch, Bertram, additional, von Felden, Johann, additional, Venerito, Marino, additional, Philipp, Alexander, additional, Finkelmeier, Fabian, additional, Ji, Fanpu, additional, Wang, Hung-Wei, additional, Rimassa, Lorenza, additional, Pinato, David J., additional, Bouattour, Mohamed, additional, Chon, Hong Jae, additional, and Pinter, Matthias, additional

Published
2024
Full Text
View/download PDF

17. Impact of HCV eradication on recurrence pattern and long‐term outcomes in patients with HCV‐related hepatocellular carcinoma undergoing radiofrequency ablation.

Author

Wu, Kuo‐Cheng, Lee, I‐Cheng, Chi, Chen‐Ta, Liu, Chien‐An, Chiu, Nai‐Chi, Hsu, Shao‐Jung, Lee, Pei‐Chang, Wu, Chi‐Jung, Luo, Jiing‐Chyuan, Hou, Ming‐Chih, and Huang, Yi‐Hsiang

Subjects
CATHETER ablation, OVERALL survival, HEPATOCELLULAR carcinoma, DISEASE relapse, TREATMENT effectiveness
Abstract

Summary: Background: The benefits of HCV eradication on distinct recurrence patterns and long‐term hepatic outcomes in patients with hepatocellular carcinoma (HCC) undergoing radiofrequency ablation (RFA) remain uncertain. This study aims to assess the impact of HCV eradication on HCC recurrence patterns and long‐term hepatic outcomes after RFA and to identify predictors of recurrence in patients achieving sustained virological response (SVR). Methods: We retrospectively enrolled 274 patients receiving RFA for HCV‐related HCC, including 73 and 88 patients treated with interferon‐based (IFN) and direct‐acting antivirals (DAA) therapy, respectively. We analysed factors associated with local tumour progression (LTP), distant recurrence, overall survival, and hepatic decompensation. Results: SVR was achieved in 49.3% of patients undergoing IFN therapy and 93.2% of patients undergoing DAA therapy. HCV eradication was not associated with LTP but significantly correlated with reduced risk of distant recurrence (by DAA: hazard ratio (HR) = 0.449, p = 0.006), overall survival (by IFN: HR = 0.242, p < 0.001; by DAA: HR = 0.274, p < 0.001) and hepatic decompensation (by IFN: HR = 0.313, p = 0.004; by DAA: HR = 0.281, p < 0.001). The benefits of achieving SVR in terms of overall survival and hepatic decompensation remained significant in subgroups of patients with and without recurrence. Patients with SVR showed a significant decline in FIB‐4 score and a higher proportion of ALBI grade improvement. Among SVR patients, the IMbrave050 criteria predicted LTP but not distant recurrence, whereas the FIB‐4 score after SVR, rather than the baseline FIB‐4, predicted distant recurrence. Conclusions: HCV eradication was associated with a significant reduction in distant recurrence, mortality and hepatic decompensation following RFA in patients with HCV‐related HCC. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma– with Emphasis on Locoregional Therapy for Oligoprogression.

Author

Liu, Tsung-Hao, Chen, San-Chi, Rau, Kun-Ming, Lu, Li-Chun, Lin, Po-Ting, Su, Yung-Yeh, Teng, Wei, Lai, Shiue-Wei, Yeh, Ren-Hua, Kao, Tsui-Mai, Lee, Pei-Chang, Wu, Chi-Jung, Chen, Chien-Hung, Hsu, Chih-Hung, Lin, Shi-Ming, Huang, Yi-Hsiang, Chen, Li-Tzong, Cheng, Ann-Lii, and Shen, Ying-Chun

Subjects
IMMUNE checkpoint inhibitors, CHRONIC active hepatitis, VIRAL hepatitis, OVERALL survival, HEPATOCELLULAR carcinoma
Abstract

Introduction: The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods: Patients with advanced HCC who received immune checkpoint inhibitor (ICI)-based immunotherapy and achieved durable responses were retrospectively included. A durable response was defined as partial response (PR) or stable disease (SD) per RECIST 1.1 for more than 8 months after initiation of immunotherapy. Oligoprogression and polyprogression were defined as progression at ≤3 and >3 lesions, respectively. Results: A total of 91 durable responders (63 PR and 28 SD) were identified. The majority had chronic viral hepatitis (n = 69, 75.8%). Forty-seven (51.6%) and 44 (48.4%) patients received the index immunotherapy as first-line and second- or beyond-line therapy, respectively. Fifty-four (59.3%) patients subsequently developed progression, with a predominant pattern of oligoprogression (66.7%). The median overall survival (OS) was 46.2 months (95% CI: 34.1–58.3). For patients with subsequent progression, employment of locoregional therapy (LRT) for progression was associated with prolonged OS (univariate analysis: hazard ratio [HR] 0.397, p = 0.009; multivariate analysis: HR 0.363, p = 0.050). Patients with oligoprogression who received LRT showed longer median OS than those who did not (48.4 vs. 20.5 months, p < 0.001). In contrast, the median OS of patients with polyprogression who received LRT was not different from those without LRT (27.7 vs. 25.5 months, p = 0.794). Conclusion: Approximately 60% of the post-immunotherapy durable responders of HCC subsequently develop progression. Proactive LRT may further rescue patients who develop subsequent oligoprogression. Prospective studies are mandatory to clarify the proper management of durable responders with subsequent progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

19. Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction.

Author

Fulgenzi, Claudia Angela Maria, Scheiner, Bernhard, D'Alessio, Antonio, Mehan, Aman, Manfredi, Giulia F., Celsa, Ciro, Nishida, Naoshi, Ang, Celina, Marron, Thomas U., Wu, Linda, Saeed, Anwaar, Wietharn, Brooke, Cammarota, Antonella, Pressiani, Tiziana, Pinter, Matthias, Sharma, Rohini, Cheon, Jaekyung, Huang, Yi-Hsiang, Lee, Pei-Chang, and Phen, Samuel

Published
2024
Full Text
View/download PDF

20. Fecal Carriage of Multidrug-Resistant Organisms Increases the Risk of Hepatic Encephalopathy in Cirrhotic Patients: Insights from Gut Microbiota and Metabolite Features

Author

Wu, Peishan, primary, Lee, Pei-Chang, additional, Chang, Tien-En, additional, Hsieh, Yun-Cheng, additional, Chiou, Jen-Jie, additional, Lin, Chao-Hsiung, additional, Huang, Yi-Long, additional, Lin, Yi-Tsung, additional, Huo, Teh-Ia, additional, Schnabl, Bernd, additional, Lee, Kuei-Chuan, additional, and Hou, Ming-Chih, additional

Published
2024
Full Text
View/download PDF

23. Feasibility estimation of injected hydrodissection before definitive radiotherapy of pancreatic adenocarcinoma

Author

Wu, Yuan-Hung, primary, Shen, Shu-Huei, additional, Wang, Yen-Po, additional, Chang, Nai-Wen, additional, Lee, Pei-Chang, additional, Li, Chung-Pin, additional, Lan, Keng-Li, additional, Shiau, Cheng-Yin, additional, Hu, Yu-Wen, additional, Huang, Pin-I, additional, Hsu, Chen-Xiong, additional, Yen, Sang-Hue, additional, and Hsu, Shih-Ming, additional

Published
2024
Full Text
View/download PDF

25. Efficacy of immune checkpoint inhibitors in patients with HIV-associated unresectable HCC (uHCC): Propensity-score matched analyses from two international consortia.

Author

Fulgenzi, Claudia A.M., primary, El Zarif, Talal, additional, Nassar, Amin, additional, Adib, Elio, additional, Bellmunt, Joaquim, additional, Marron, Thomas Urban, additional, Lorentsen, Michael, additional, McKay, Rana R., additional, Baena, Javier, additional, Ang, Celina, additional, Rimassa, Lorenza, additional, Kudo, Masatoshi, additional, Parisi, Alessandro, additional, Saeed, Anwaar, additional, Lee, Pei-Chang, additional, Parikh, Neehar, additional, Pinter, Matthias, additional, Cortellini, Alessio, additional, Naqash, Abdul Rafeh, additional, and Pinato, David James, additional

Published
2024
Full Text
View/download PDF

26. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

Author

Balcar, Lorenz, primary, Scheiner, Bernhard, additional, Maria Fulgenzi, Claudia Angela, additional, D’Alessio, Antonio, additional, Pomej, Katharina, additional, Roig, Marta Bofill, additional, Meyer, Elias Laurin, additional, Cheon, Jaekyung, additional, Nishida, Naoshi, additional, Lee, Pei-Chang, additional, Wu, Linda, additional, Ang, Celina, additional, Krall, Anja, additional, Saeed, Anwaar, additional, Stefanini, Bernardo, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Wietharn, Brooke, additional, Parisi, Alessandro, additional, Huang, Yi-Hsiang, additional, Phen, Samuel, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Vogel, Arndt, additional, von Felden, Johann, additional, Schulze, Kornelius, additional, Silletta, Marianna, additional, Trauner, Michael, additional, Samson, Adel, additional, Wege, Henning, additional, Piscaglia, Fabio, additional, Galle, Peter R., additional, Stauber, Rudolf, additional, Kudo, Masatoshi, additional, Singal, Amit G., additional, Itani, Aleena, additional, Ulahannan, Susanna V., additional, Parikh, Neehar D., additional, Cortellini, Alessio, additional, Kaseb, Ahmed, additional, Rimassa, Lorenza, additional, Chon, Hong Jae, additional, Pinato, David J., additional, and Pinter, Matthias, additional

Published
2023
Full Text
View/download PDF

27. Mac-2-Binding Protein Glycosylation Isomer to Albumin Ratio Predicts Bacterial Infections in Cirrhotic Patients.

Author

Wu, Pei-Shan, Hsieh, Yun-Cheng, Lee, Pei-Chang, Yang, Tsung-Chieh, Chen, Yu-Jen, Yang, Ying-Ying, Huang, Hui-Chun, Hsu, Shao-Jung, Huo, Teh-Ia, Lee, Kuei-Chuan, Lin, Han-Chieh, and Hou, Ming-Chih

Subjects
BACTERIAL diseases, ISOMERS, RECEIVER operating characteristic curves, HEPATIC fibrosis, PROPORTIONAL hazards models
Abstract

Introduction: Mac-2-binding protein glycosylation isomer (M2BPGi) is a novel biomarker for liver fibrosis, but little is known about its role in cirrhosis-associated clinical outcomes. This study aimed to investigate the predictive role of M2BPGi in cirrhosis-associated complications. Methods: One hundred and forty-nine cirrhotic patients were retrospectively enrolled. Patients were followed up for 1 year, and cirrhosis-associated clinical events were recorded. Receiver operating characteristic curve (ROC) analysis was used to establish the values of the predictive models for cirrhotic outcomes, and Cox proportional hazards regression models were used to identify predictors of clinical outcomes. Results: Sixty (40.3%) patients experienced cirrhosis-associated clinical events and had higher M2BPGi levels compared to those without events (8.7 vs. 5.1 cutoff index, p < 0.001). The most common cirrhosis-associated complications were bacterial infections (24.2%). On ROC analysis, M2BPGi to albumin ratio (M2BPGi/albumin) had comparable discriminant abilities for all cirrhosis-associated events (area under the ROC curve [AUC] = 0.74) compared with M2BPGi, Child-Pugh, model for end-stage liver disease, albumin-bilirubin scores, and neutrophil-to-lymphocyte ratio and was superior to M2BPGi alone for all bacterial infectious events (AUC = 0.80). Cox regression analysis revealed that the M2BPGi/albumin, but not M2BPGi alone, independently predicted all cirrhosis-associated events (hazard ratio [HR] = 1.34, p = 0.038) and all bacterial infectious events (HR = 1.51, p = 0.011) within 1 year. However, M2BPGi/albumin did not predict other cirrhotic complications and transplant-free survival. Discussion/Conclusion: M2BPGi/albumin might serve as a potential prognostic indicator for patients with cirrhosis, particularly for predicting bacterial infections. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Author

Joerg, Vincent, primary, Scheiner, Bernhard, additional, D´Alessio, Antonio, additional, Fulgenzi, Claudia A.M., additional, Schönlein, Martin, additional, Kocheise, Lorenz, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Kaseb, Ahmed, additional, Wang, Yinghong, additional, Mathew, Antony, additional, Kuang, Andrew, additional, Muzaffar, Mahvish, additional, Abugabal, Yehia I., additional, Chamseddine, Shadi, additional, Phen, Samuel, additional, Cheon, Jaekyung, additional, Lee, Pei-Chang, additional, Balcar, Lorenz, additional, Krall, Anja, additional, Ang, Celina, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Bengsch, Bertram, additional, Rimassa, Lorenza, additional, Weinmann, Arndt, additional, Stauber, Rudolf, additional, Korolewicz, James, additional, Pinter, Matthias, additional, Singal, Amit G., additional, Chon, Hong Jae, additional, Pinato, David J., additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2023
Full Text
View/download PDF

32. Efficacy and tolerability of atezolizumab and bevacizumab in patients with hepatocellular carcinoma previously treated with systemic therapy: a global, observational study

Author

Jörg, Vincent, primary, Scheiner, Bernhard, additional, D’Alessio, Antonio, additional, Fulgenzi, Claudia, additional, Schoenlein, Martin, additional, Kocheise, Lorenz, additional, Lohse, Ansgar W., additional, Huber, Samuel, additional, Wege, Henning, additional, Kaseb, Ahmed, additional, Wang, Yinghong, additional, Muzaffar, Mahvish, additional, Abugabal, Yehia, additional, Chamseddine, Shadi, additional, Phen, Samuel, additional, Cheon, Jaekyung, additional, Lee, Pei-Chang, additional, Balcar, Lorenz, additional, Krall, Anja, additional, Ang, Celina, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Huang, Yi-Hsiang, additional, Bengsch, Bertram, additional, Rimassa, Lorenza, additional, Weinmann, Arndt, additional, Stauber, Rudolf E., additional, Korolewicz, James, additional, Pinter, Matthias, additional, Singal, Amit, additional, Chon, Hong Jae, additional, Pinato, David J., additional, Schulze, Kornelius, additional, and von Felden, Johann, additional

Published
2023
Full Text
View/download PDF

34. Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction

Author

Fulgenzi, Claudia, primary, D’Alessio, Antonio, additional, Scheiner, Bernhard, additional, Nishida, Naoshi, additional, Ang, Celina, additional, Marron, Thomas, additional, Wu, Linda, additional, Saeed, Anwaar, additional, Wietharn, Brooke, additional, Cammarota, Antonella, additional, Pressiani, Tiziana, additional, Pinter, Matthias, additional, Sharma, Rohini, additional, Cheon, Jaekyung, additional, Huang, Yi-Hsiang, additional, Lee, Pei-Chang, additional, Phen, Samuel, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Napolitano, Andrea, additional, Vivaldi, Caterina, additional, Salani, Francesca, additional, Masi, Gianluca, additional, Bettinger, Dominik, additional, Thimme, Robert, additional, Vogel, Arndt, additional, Schoenlein, Martin, additional, Schulze, Kornelius, additional, von Felden, Johann, additional, Wege, Henning, additional, Galle, Peter, additional, Pirisi, Mario, additional, Park, Joong-Won, additional, Kudo, Masatoshi, additional, Rimassa, Lorenza, additional, Singal, Amit, additional, Cortellini, Alessio, additional, Chon, Hong Jae, additional, Ghittoni, Giorgia, additional, Camma, Calogero, additional, Stefanini, Benedetta, additional, Trevisani, Franco, additional, Giannini, Edoardo Giovanni, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

35. Vitamin D deficiency associates with gut dysbiosis, endotoxemia and the risk of infectious complications in patients with liver cirrhosis

Author

Lee, Pei-Chang, primary, Lee, Kuei-Chuan, additional, Lu, Hsiao-Sheng, additional, Chen, Yu-Jen, additional, Cheng, Tsung-Yi, additional, Yang, Tsung-Chieh, additional, Chiou, Jen-Jie, additional, Huang, Chi-Wei, additional, Yang, Ueng-Cheng, additional, Huang, Yi-Hsiang, additional, and Hou, Ming-Chih, additional

Published
2023
Full Text
View/download PDF

41. Supplementary Figure from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

Author

Chiang, Nai-Jung, primary, Tan, Kien Thiam, primary, Bai, Li-Yuan, primary, Hsiao, Chin-Fu, primary, Huang, Chung-Yu, primary, Hung, Yi-Ping, primary, Huang, Chien-Jui, primary, Chen, San-Chi, primary, Shan, Yan-Shen, primary, Chao, Yee, primary, Huang, Yi-Hsiang, primary, Lee, I-Cheng, primary, Lee, Pei-Chang, primary, Su, Yung-Yeh, primary, Chen, Shu-Jen, primary, Yeh, Chun-Nan, primary, Chen, Li-Tzong, primary, and Chen, Ming-Huang, primary

Published
2023
Full Text
View/download PDF

42. Supplementary Table from Impaired Chromatin Remodeling Predicts Better Survival to Modified Gemcitabine and S-1 plus Nivolumab in Advanced Biliary Tract Cancer: A Phase II T1219 Study

Author

Chiang, Nai-Jung, primary, Tan, Kien Thiam, primary, Bai, Li-Yuan, primary, Hsiao, Chin-Fu, primary, Huang, Chung-Yu, primary, Hung, Yi-Ping, primary, Huang, Chien-Jui, primary, Chen, San-Chi, primary, Shan, Yan-Shen, primary, Chao, Yee, primary, Huang, Yi-Hsiang, primary, Lee, I-Cheng, primary, Lee, Pei-Chang, primary, Su, Yung-Yeh, primary, Chen, Shu-Jen, primary, Yeh, Chun-Nan, primary, Chen, Li-Tzong, primary, and Chen, Ming-Huang, primary

Published
2023
Full Text
View/download PDF

43. Endoscopic variceal ligation versus propranolol for the primary prevention of oesophageal variceal bleeding in patients with hepatocellular carcinoma: an open-label, two-centre, randomised controlled trial

Author

Yang, Tsung-Chieh, Chen, Wen-Chi, Hou, Ming-Chih, Chen, Ping-Hsien, Lee, Pei-Chang, Chang, Chung-Yu, Lu, Hsiao-Sheng, Chen, Yu-Jen, Hsu, Shao-Jung, Huang, Hui-Chun, Luo, Jiing-Chyuan, Huang, Yi-Hsiang, and Lee, Fa-Yauh

Abstract

ObjectiveThis randomised trial aimed to address whether endoscopic variceal ligation (EVL) or propranolol (PPL) is more effective at preventing initial oesophageal variceal bleeding (EVB) in patients with hepatocellular carcinoma (HCC).DesignPatients with HCC and medium-to-large oesophageal varices (EVs) but without previous EVB were randomised to receive EVL (every 3–4 weeks until variceal eradication) or PPL (up to 320 mg daily) at a 1:1 ratio. Long-term follow-up data on EVB, other upper gastrointestinal bleeding (UGIB), non-bleeding liver decompensation, overall survival (OS) and adverse events (AEs) were analysed using competing risk regression.ResultsBetween June 2011 and April 2021, 144 patients were randomised to receive EVL (n=72) or PPL (n=72). In the EVL group, 7 patients experienced EVB, and 30 died; in the PPL group, 19 patients had EVB, and 40 died. The EVL group had a lower cumulative incidence of EVB (Gray’s test, p=0.009) than its counterpart, with no mortality difference (Gray’s test, p=0.085). For patients with Barcelona Clinic Liver Cancer (BCLC) stage A/B, EVL was better than PPL in reducing EVB (p<0.001) and mortality (p=0.003). For patients beyond BCLC stage B, between-group outcomes were similar. Other UGIB, non-bleeding liver decompensation and AEs did not differ between groups. A competing risk regression model confirmed the prognostic value of EVL.ConclusionEVL is superior to PPL in preventing initial EVB in patients with HCC. The benefits of EVL on EVB and OS may be limited to patients with BCLC stage A/B and not to those with BCLC stage C/D.Trial registration numberNCT01970748.

Published
2024
Full Text
View/download PDF

44. Assuring safety of fecal microbiota transplantation in the COVID‐19 era: A single‐center experience.

Author

Chang, Tien‐En, Lee, Kuei‐Chuan, Lee, Pei‐Chang, Wang, Yen‐Po, Lin, Yi‐Tsung, Huang, Hui‐Chun, Luo, Jiing‐Chyuan, Ho, Hsiang‐Ling, Huang, Yi‐Hsiang, and Hou, Ming‐Chih

Subjects
SARS-CoV-2, COVID-19 pandemic, FECAL microbiota transplantation, NUCLEIC acid amplification techniques, MULTIDRUG resistance
Abstract

Background and Aim: Fecal microbiota transplantation (FMT) is used to treat recurrent or refractory Clostridioides difficile infection (CDI). In the past, screening of fecal donors required surveillance of personal behavior, medical history, and diseases that could be transmitted by the blood or fecal–oral route. In addition, the exclusion of multidrug‐resistant organisms (MDROs) has been recommended since 2018. This task has become more complicated in the era of the coronavirus disease‐2019 (COVID‐19) pandemic. To prevent fecal transmission of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), it is crucial to commence screening for SARS‐CoV‐2, alongside other traditional tests. Our aim was to investigate whether hidden carriers of SARS‐CoV‐2 were enrolled for stool donation, and the status of the presence or incidence of MDRO during fecal donation in Taiwan. Methods: Fecal products collected from March 2019 to December 2022 were tested for MDRO and nucleic acid amplification tests for SARS‐CoV‐2 using the pooling method. The period of fecal product collection crossed the time before and during the COVID pandemic in Taiwan. Results: A total of 151 fecal samples were collected. The fecal products were tested using polymerase chain reaction (PCR) to detect SARS‐CoV‐2. The results were negative for all stocks. This was similar to the results of MDRO testing. The safety of FMT products has been guaranteed during the pandemic. Conclusion: Our FMT center produced MDRO‐free and COVID‐19‐free products before and during the COVID‐19 outbreak in Taiwan. Our protocol was effective for ensuring the safety of FMT products. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

45. Outcomes of beta blocker use in advanced hepatocellular carcinoma treated with immune checkpoint inhibitors

Author

Wu, Y. Linda, primary, van Hyfte, Grace, additional, Özbek, Umut, additional, Reincke, Marlene, additional, Gampa, Anuhya, additional, Mohamed, Yehia I., additional, Nishida, Naoshi, additional, Wietharn, Brooke, additional, Amara, Suneetha, additional, Lee, Pei-Chang, additional, Scheiner, Bernhard, additional, Balcar, Lorenz, additional, Pinter, Matthias, additional, Vogel, Arndt, additional, Weinmann, Arndt, additional, Saeed, Anwaar, additional, Pillai, Anjana, additional, Rimassa, Lorenza, additional, Naqash, Abdul Rafeh, additional, Muzaffar, Mahvish, additional, Huang, Yi-Hsiang, additional, Kaseb, Ahmed O., additional, Kudo, Masatoshi, additional, Pinato, David J., additional, and Ang, Celina, additional

Published
2023
Full Text
View/download PDF

46. Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma: An international observational study

Author

Talbot, Thomas, primary, D'Alessio, Antonio, additional, Pinter, Matthias, additional, Balcar, Lorenz, additional, Scheiner, Bernhard, additional, Marron, Thomas U., additional, Jun, Tomi, additional, Dharmapuri, Sirish, additional, Ang, Celina, additional, Saeed, Anwaar, additional, Hildebrand, Hannah, additional, Muzaffar, Mahvish, additional, Fulgenzi, Claudia A. M., additional, Amara, Suneetha, additional, Naqash, Abdul Rafeh, additional, Gampa, Anuhya, additional, Pillai, Anjana, additional, Wang, Yinghong, additional, Khan, Uqba, additional, Lee, Pei‐Chang, additional, Huang, Yi‐Hsiang, additional, Bengsch, Bertram, additional, Bettinger, Dominik, additional, Mohamed, Yehia I., additional, Kaseb, Ahmed, additional, Pressiani, Tiziana, additional, Personeni, Nicola, additional, Rimassa, Lorenza, additional, Nishida, Naoshi, additional, Kudo, Masatoshi, additional, Weinmann, Arndt, additional, Galle, Peter R., additional, Muhammed, Ambreen, additional, Cortellini, Alessio, additional, Vogel, Arndt, additional, and Pinato, David J., additional

Published
2023
Full Text
View/download PDF

48. Lockdown period during SARS COVID-19 endemic outbreak in Taiwan did not cause an increase of the complications nor mortality of patients received endoscopic retrograde cholangiopancreatography: A single-center retrospective study

Author

Li, Chia-Ju, primary, Chang, Tien-En, additional, Hou, Ming-Chih, additional, Huang, Yi-Hsiang, additional, Lee, Pei-Chang, additional, Chang, Nai-Wen, additional, Chen, Yu-Jen, additional, and Lee, Fa-Yuah, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results